Latest Breaking News On - வாட்டர் மில் சொத்து மேலாண்மை - Page 1 : comparemela.com

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Ziopharm Oncology (NASDAQ:ZIOP) were jumping 10.8% higher as of 11:55 a.m. EST on Friday. The solid gain came after the company provided its fourth-quarter update following the market close on Thursday. Ziopharm announced a net loss in the fourth quarter of $22.8 million, or $0.11 per share. There were two bigger stories, though. The U.S. Food and Drug Administration (FDA) gave a green light for Ziopharm to begin testing its experimental T cell receptor-engineered T cell (TCR-T) therapies in phase 1/2 clinical studies. Also, Laurence Cooper is stepping down as CEO with board member Heidi Hagen taking his place as interim CEO. 

Bob postmaLaurence cooperHeidi hagenDrug administrationMd anderson cancer centerZiopharm oncologyWall streetCancer centerWatermill asset managementபாப் பொசடமகலாரன்ஸ் கூப்பர்ஹெய்டி ஹேகன்ம்ட் ஆண்டர்சன் புற்றுநோய் மையம்சுவர் தெருபுற்றுநோய் மையம்வாட்டர் மில் சொத்து மேலாண்மை